DXL CEO says big-and-tall retailer could benefit from GLP-1 drugs
Men's big-and-tall retailer DXL is expecting, perhaps ironically, to benefit from the popularity of GLP-1 drugs such as ...
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Landmark Study Explains Why Obesity Drugs Work Differently for Women and Men
With two billion people overweight or obese and the obesity treatment market expected to reach $200 billion by 2031, Olio ...
MedPage Today on MSN1d
Study: Obesity Linked With 16 Common Adverse Health Conditions
Obesity was tied with an increased risk of developing 16 health outcomes, a large longitudinal study showed. Risks correlated ...
Reuters on MSN8d
Eli Lilly beats Novo Nordisk to launch weight-loss drug Mounjaro in India
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Eli Lilly beats Novo Nordisk to launch weight-loss drug Mounjaro in India, at $50 for 5 mg vial
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
The Print8d
Eli Lilly launches weight-loss drug Mounjaro in India at $50 for 5 mg vial, beating Novo Nordisk
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
pharmaphorum1d
Lilly adds another sales channel for obesity drug Zepbound
"Offering Zepbound single-dose vials […] through another ... Ro was launched (as Roman) in 2017 and initially focused on men's health issues like erectile dysfunction before expanding its ...
Healio3d
All-cause, cardiovascular mortality risks in OSA fall with positive airway pressure use
Use of positive airway pressure therapy decreased the risk for all-cause and cardiovascular mortality in adults with ...